Divi's Laboratories (NSE:DIVISLAB) Operating Margin %: 28.75% (As of Mar. 2026) — Near Median


NSE:DIVISLAB Divi's Laboratories Ltd NSE:DIVISLAB
94 GF Score
Price ₹6,753.50
GF Value ₹6,729.63
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Divi's Laboratories Operating Margin %?

Divi's Laboratories NSE:DIVISLAB +0.10% 94 Operating Margin % is 28.75% as of Mar. 2026, which is 5% below its 10-year median of 30.30. GuruFocus rates NSE:DIVISLAB with a GF Score™ of 94/100 and a GF Value™ of ₹6,729.63 (Fairly Valued). The stock has 5 warning signs investors should review. Among 955 Drug Manufacturers companies, Divi's Laboratories ranks better than 92.57% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Divi's Laboratories's Operating Income for the three months ended in Mar. 2026 was ₹8,140 Mil. Divi's Laboratories's Revenue for the three months ended in Mar. 2026 was ₹28,310 Mil. Therefore, Divi's Laboratories's Operating Margin % for the quarter that ended in Mar. 2026 was 28.75%.

Warning Sign:

Divi's Laboratories Ltd operating margin has been in a 5-year decline. The average rate of decline per year is -7.7%.

The historical rank and industry rank for Divi's Laboratories's Operating Margin % or its related term are showing as below:

NSE:DIVISLAB' s Operating Margin % Range Over the Past 10 Years
Min: 23.5   Med: 30.3   Max: 40.61
Current: 28.2


NSE:DIVISLAB's Operating Margin % is ranked better than
92.57% of 955 companies
in the Drug Manufacturers industry
Industry Median: 7.45 vs NSE:DIVISLAB: 28.20

Divi's Laboratories's 5-Year Average Operating Margin % Growth Rate was -7.70% per year.

Divi's Laboratories's Operating Income for the three months ended in Mar. 2026 was ₹8,140 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was ₹29,780 Mil.


Divi's Laboratories  (NSE:DIVISLAB) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Divi's Laboratories Operating Margin % Related Terms


Divi's Laboratories Operating Margin % Historical Data

* Premium members only.

The historical data trend for Divi's Laboratories's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Divi's Laboratories Operating Margin % Chart

Divi's Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 40.61 26.44 23.50 27.41 28.20

Divi's Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.14 25.60 28.55 29.65 28.75

NSE:DIVISLAB vs ZTS: Operating Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Divi's Laboratories's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Divi's Laboratories Operating Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Divi's Laboratories's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Divi's Laboratories's Operating Margin % falls into.


NSE:DIVISLAB
94GF Score
Divi's Laboratories Ltd NSE:DIVISLAB
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Divi's Laboratories Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Divi's Laboratories's Operating Margin % for the fiscal year that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (A: Mar. 2026 ) / Revenue (A: Mar. 2026 )
=29780 / 105600
=28.20 %

Divi's Laboratories's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=8140 / 28310
=28.75 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 28.75% mean?
Divi's Laboratories (NSE:DIVISLAB) has a Operating Margin % of 28.75% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Divi's Laboratories and its competitors. This is near median its historical median of 30.30. Over the past decade, Divi's Laboratories' Operating Margin % has ranged from 23.50 to 40.61. According to the industry distribution chart, Divi's Laboratories ranks #71 out of 955 companies in the Drug Manufacturers industry, placing it in the top 7.4%.
Is Divi's Laboratories' Operating Margin % too high?
Divi's Laboratories' current Operating Margin % of 28.75% is near median its 10-year median of 30.30. Over the past 10 years, this metric has ranged from a low of 23.50 to a high of 40.61. The Drug Manufacturers industry median Operating Margin % is 7.45. Divi's Laboratories' value of 28.75% is 285.9% above this industry median. Based on the distribution chart, Divi's Laboratories ranks #71 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Divi's Laboratories has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Divi's Laboratories' Operating Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Divi's Laboratories ranks #71 out of 955 companies for Operating Margin %. This places Divi's Laboratories in the top 7% of its industry — outperforming the majority of peers. The industry median Operating Margin % is 7.45. Divi's Laboratories' value of 28.75% is 285.9% above this benchmark. Historically, Divi's Laboratories' own Operating Margin % has ranged from 23.50 to 40.61 over the past decade. While the company's 10-year median is 30.30 vs. the industry median of 7.45, Divi's Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.45, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Divi's Laboratories's current Operating Margin % of 28.75% is 285.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Divi's Laboratories and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Divi's Laboratories's current Operating Margin % is 28.75%, which is near median its own 10-year median of 30.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Divi's Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Divi's Laboratories (NSE:DIVISLAB) is currently considered Fairly Valued. The stock's GF Value™ is ₹6,729.63, compared to a current price of ₹6,753.50 — trading 0.4% above its estimated fair value. The current Operating Margin % is 28.75%, which is near median its 10-year median of 30.30 and 285.9% above the Drug Manufacturers industry median of 7.45. Divi's Laboratories' overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Divi's Laboratories (NSE:DIVISLAB), the current Operating Margin % is 28.75% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Divi's Laboratories (NSE:DIVISLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Divi's Laboratories stock appears to be overvalued. The current stock price of ₹6,753.50 is trading 0.4% above its estimated GF Value™ of ₹6,729.63. GuruFocus considers Divi's Laboratories to be Fairly Valued.

Key valuation signals for NSE:DIVISLAB:

  • Operating Margin %: 28.75% (near median its 10-year median of 30.30)
  • GF Value™: ₹6,729.63 vs. price of ₹6,753.50 (0.4% above fair value)
  • GF Score™: 94/100 with 5 warning signs
  • Industry Position: 285.9% above the Drug Manufacturers median (#71 of 955)

No single metric tells the full story. See the NSE:DIVISLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Divi's Laboratories Business Description

Other Exchanges 532488:India
Address Cyber Hills, Divi Towers, 1-72/23(P)/DIVIS/303, Gachibowli, Hyderabad, TG, IND, 500032
Divi's Laboratories Ltd is a specialty and generic drug manufacturing company. It is engaged in the manufacture of Active Pharmaceutical ingredients (API), Intermediates, and Nutraceutical ingredients, with a predominance in exports. It also, through its custom synthesis, supports pharma companies for their patented products business from gram-scale requirements for clinical trials to launch, as well as late-life cycle management. Geographically, the company derives maximum revenue from Europe, and the rest from America, India, Asia (excluding India), and the Rest of the world.
94GF Score

Get the complete analysis for NSE:DIVISLAB

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹6,753.50
Price
₹6,729.63
GF Value